News

Ankylosing Spondylitis: Recent Developments in Treatment


 

EXPERT ANALYSIS FROM THE CONGRESS OF CLINICAL RHEUMATOLOGY

However, while the response rate was significantly higher than with placebo, the relative change in BASDAI50 was relatively modest and not of the same magnitude typically seen with anti-TNF drugs, he said.

"So I think the jury is still out on the anti-IL17," he concluded.

Dr. Inman disclosed that he is a consultant for Abbott Laboratories, Merck , Pfizer, and Sanofi-Aventis.

Pages

Recommended Reading

Statin Reverses Tofacitinib-Induced Lipid Changes in RA
MDedge Internal Medicine
Patient Subgroup Response to Belimumab Remains Unclear
MDedge Internal Medicine
Black Osteoarthritis Patients Tend to Balk at Total Knee Replacement
MDedge Internal Medicine
Bosentan May Reduce Skin Fibrosis in Scleroderma
MDedge Internal Medicine
Unguided Intra-Articular Injections of Betamethasone Safe, Effective
MDedge Internal Medicine
Rilonacept Reduces Gout Flares Triggered by Urate-Lowering Therapy
MDedge Internal Medicine
Induction-Maintenance Treatment Succeeds in Early RA
MDedge Internal Medicine
Rituximab Deemed Useful for Certain Lupus Subgroups
MDedge Internal Medicine
Rheumatoid Society Addresses Employment Disparity
MDedge Internal Medicine
Socioeconomic Factors Linked to Complications of Giant Cell Arteritis
MDedge Internal Medicine